Citi Reiterates Sell Rating on Hims and Hers (HIMS), Comments on Novo's Wegovy Price Promo: 'We see this as another potential headwind for HIMS

Citi Drops Third Note on Hims and Hers (HIMS) Inside 20 Hours: 'HIMS is now offering discounts on its bundles, effectively passing through the price discount'

(Updated - May 22, 2025 2:52 PM EDT)

Citi analyst Daniel Grosslight reiterated a Sell rating and $30.00 price target on Hims and Hers (NYSE: HIMS)

The analyst comments "In response to Novo lowering the cash pay price of Wegovy to $199 for the first month... More

Hims & Hers Health: Analysts remain bearish

Investing.com -- Analysts at Citi and Bank of America are maintaining a cautious stance on Hims & Hers Health (NYSE: HIMS) as competition in the GLP-1 space intensifies and growth begins to moderate.

In a note Thursday, Citi flagged potential pressure from Evernorths newly announced benefit that caps patient out-of-pocket costs for GLP-1... More

Morgan Stanley Reiterates Equalweight Rating on Hims and Hers (HIMS)

Morgan Stanley analyst Craig Hettenbach reiterated an Equalweight rating and $40.00 price target on Hims and Hers (NYSE: HIMS).

The analyst comments "Him & Hers app downloads increased 25% y/y... Third party data suggests 25% y/y growth in app downloads in the month of April ( Exhibit 2 ). App downloads... More

Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS)

Truist Securities analyst Jailendra Singh reiterated a Hold rating and $45.00 price target on Hims and Hers (NYSE: HIMS).

The analyst comments "Thoughts on Evernorth's Weight Loss Drugs Coverage Announcement. On 5/21, after the close, Evernorth (part of Cigna, CI, Buy, MacDonald) announced a pharmacy benefit offering that would make weight loss medications Wegovy and Zepbound available at a monthly cost not exceeding $200 to patients, with the added benefit of counting towards the patient's annual... More

BofA Securities Negative on Hims and Hers (HIMS): 'Observed total sales and GLP-1 sales decline in April'

BofA Securities analyst Michael Cherny reiterated an Underperform rating and $28.00 price target on Hims and Hers (NYSE: HIMS)

The analyst comments "Observed sales data continues to weaken sequentially. Observed sales growth y/y decelerated 6ppts from March with sales down 6% m/m (3% adj. for days) and GLP-1 sales declined for the 2nd consecutive month. While... More

Citi Reiterates Sell Rating on Hims and Hers (HIMS), PT $30, 'we do think that this will be a slight headwind to HIMS'

Citi analyst Daniel Grosslight reiterated a Sell rating and $30.00 price target on Hims and Hers (NYSE: HIMS)

The analyst comments "This afternoon, Evernorth announced it is launching a new benefit option that caps patient OOP costs for Wegovy and Zepbound at... More